Should cost of care be considered in a clinical practice guideline?

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 6, Issue 3, 2008, Pages 224-226

  Evans, William K ^a,b   Brouwers, Melissa C ^b,c,d,e,f   Bell, Chaim M ^g,h  

^a HAMILTON HEALTH SCIENCES   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c CANCER CARE ONTARIO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e University of Western Ontariosearch

^f Clinical Practices Guidelines Action Group of the Canadian Strategy for Cancer Control

^g ST MICHAEL'S HOSPITAL   (Canada)

^h Ontario Health Technology Advisory Committee

Author keywords

[No Author keywords available]

Indexed keywords

CANADA; CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC ASPECT; EVIDENCE BASED PRACTICE; HEALTH CARE SYSTEM; HUMAN; LUNG NON SMALL CELL CANCER; NOTE; PRACTICE GUIDELINE; QUALITY OF LIFE;

EID: 41749091116     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2008.0020     Document Type: Note

References (8)

1. Browman GP, Levine MN, Mohide EA, et al. The practice guideline development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol 1995;13:502-512.
2. Brouwers MC, Graham ID, Hanna SE, et al. Clinician's assessments of practice guidelines in oncology: the CAPGO survey. Int J Technol Assess Health Care 2004;20:421-426.
3. Browman GP, Newman TE, Mohide EA, et al. Progress of clinical oncology guidelines development using the practice guidelines development by cycle: the role of practitioner feedback. J Clin Oncol 1998;16:1226-1231.
4. Evans WK, Nefsky M, Pater J, et al. Cancer Care Ontario's New Drug Funding Program: controlled introduction of expensive anticancer drugs. Chronic Dis Can 2002;23:152-156.
5. Reed S, Anstrom K, Bakhai A, et al. Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. Am Heart J 2005;149:434-443.
6. van Erkel AR, van den Hout WB, Pattynama PM. International differences in health care costs in Europe and the United States: do these affect the cost-effectiveness of diagnostic strategies for pulmonary embolism? Eur Radiol 1999;9:1926-1931.
7. Drummond M. Introducing economic and quality of life measurements into clinical studies. Ann Med 2001;33:344-349.
8. Evans WK, Coyle D, Gafni A, et al. Which cancer clinical trials should be considered for economic evaluation? Selection criteria from the National Cancer Institute of Canada's Working Group on Economic Analysis. Chronic Dis Can 2003;24:102-107.